False-negative scintigraphy with Tc-99m sestamibi in stage IV neuroblastoma
Makaleler > Tam Makale · 1999
Yazarlar: Zehra ÖZCAN, G ERENEL, Serap AKSOYLAR, Savaş KANSOY, Zeynep BURAK, H OZKILIC
CLINICAL NUCLEAR MEDICINE, SCI Expanded İndekslerine Giren Dergi, Uluslararası, 1999, cilt 24, ss 267-270
DOI: 10.1097/00003072-199904000-00011
Özet
Tc-99m sestamibi, originally developed for myocardial studies, has been used as a tumor-seeking agent. Recently, the agent also was reported to be a functional tracer to predict multidrug resistance-related p-glycoprotein expression in tumor tissue. The current report presents the authors' experience with sestamibi tumor scintigraphy in a neuroblastoma. Although I-131 MIBG tumor imaging and Tc-99m MDP bone scanning accurately demonstrated the extent of the disease, Tc-99m sestamibi showed no accumulation in primary and metastatic foci. Lack of sestamibi uptake was initially thought to be suggestive of failure to respond to chemotherapy because of p-glycoprotein expression. However, the patient responded well to chemotherapy and complete remission was achieved. The failure of Tc-99m sestamibi to detect a neuroblastoma and the lack of sestamibi accumulation in the tumor may not always be related to chemotherapy resistance.